LRFN5

Across TCGA pan-cancer cohorts, LRFN5 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated LRFN5 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LRFN5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRFN5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, MESO, and COAD are the cancer types where LRFN5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.256	0.809	<.001	36	view →
MESO	OS	Median	III,IV	0.069	0.580	<.001	27	view →
COAD	OS	Median	IV	0.140	0.657	.005	14	view →
OV	DFS	Median	IV	0.150	0.468	.020	12	view →
THCA	DFS	Median	All	0.062	0.909	<.001	12	view →
PAAD	OS	Median	All	0.132	0.640	.018	6	view →
PRAD	DFS	Median	All	0.598	0.935	.005	6	view →
LUAD	DFS	Median	IV	0.671	0.893	.019	4	view →
LGG	OS	Median	All	0.307	0.799	.022	3	view →
SKCM	DFS	Median	II,III,IV	0.876	0.676	.028	2	view →
LUSC	OS	Median	III,IV	0.179	0.430	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

LRFN5–ACC (OS)

Open the ACC breakdown →